Lucan-R® is indicated for:
1. Vaginal candidiasis (acute or recurrent) Candidal balanitis. The treatment of partners who present with symptomatic genital
candidiasis should be considered.
2. Mucosal candidiasis. These include oropharyngeal, oesophegeal, noninvasive bronchopulmonary infections, candiduria,
mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). Normal hosts and patients with compromised immune
function may be treated.
3. Tinea pedis, tinea cruris, tinea versicolor and dermal Candidial Infections. Lucan-R® is also indicated for nail fungal infections.
4. Systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infections of the
peritoneum, endocardium and pulmonary and urinary tracts. Candidal infections in patients with malignancy, in intensive care units or those receiving
cytotoxic or immunosuppressive therapy, may be treated.
5. Cryptococcosis, including cryptococcal meninigitis and infections of other sites (e.g. pulmonary cutaneous) normal hots and patients with acquired
immune deciency syndrome (AIDS), organ transplants or other causes of immunosuppression may be treated. Lucan-R can be used as maintainance
therapy to prevent relapse of cryptococcal disease in patients with AIDS.
6. For the prevention of fungal infections in immunocompromised patients considered at risk as a consequence of neutropenia following cytotoxic
chemotherapy or radiotherapy, including bone marrow transplant patients.
DOSAGE AND ADMINISTRATION:
Lucan-R® is administered orally. The daily dose of uconazole should be based on the nature and severity of the fungal infection. Most cases of vaginal
candiasis respond to single dose therapy. Therapy for those types of infection requiring multipile dose treatment should be continued until clinical
parameters or laboratory test indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active
infection. Patients with AIDS and crytococcal meningits usually require maintainance therapy to prevent relapse.
Adults:
1. Candidal balanitis or vaginitis: 150mg single oral dose
2 . Mucosal Candidiasis:
Oropharyngeal candidiasis: the recommamended dose is 50 mg once daily for 7 to 14 days. Treatment should not normally exceed 14 days except in
severily immunocompromised patients.
Atrophic oral candidiasis associated with dentures: the recommended dose is 50 mg once daily for 14 days, administared concurrently with local anti
septic measures to the denture.
For other candidal infections of the mucosa, (except genital candidiasis see above), e.g. oesophagitis, non-invasive bronchopulmonary infections,
candiduria, mucocutaneous candidiasis etc. the recommended dose is 50 mg daily, given for 14 to 30 days.
In unusually dicult cases of mucosal candidal infections the dose may be increased to 100mg daily.
3. For tinea pedis, corporis, cruris, versicolor and dermal Candidal infections: the recommended dose is 50 mg once daily. Duration of treatment is
normally 2 to 4 weeks but tinea pedis may require treatment for up to 6 weeks. Duration of treatment should not exceed 6 weeks.
4. For candidaemia, disseminated candidaemia and other invasive candidal infections : the recommended dose is 400 mg on the rst day followed
by 200 mg-400 mg once daily. Depending on the clinical response the dose may be increased to 400 mg once daily. Duration of treatment is based upon
the clinical response.
5. For cryptococcal meningitis and cryptococcal infections at other sites: the recommanded dose is 400 mg on rst day follwed by 200 mg once daily.
Duration of treatment for cryptoccoal infections will depend on the clinical and mycological response, but is usually at least 6 to 8 weeks for
cryptococcal meningitis.
For the prevention of relapse of cryptococcal meningitis in patients with AIDS, after the patient recives a full course of primary therapy,
Lucan-R®may be administerd indenitely at a daily dose of 100-200 mg.
6 . For the prevention of fungal infections in immunocompromised patients considered at a risk as a consequence of neutropenia following
cytotoxic chemotherapy of radiotherapy, the dose should be 50-400 mg daily based on the patients risk for developing fungal infection. For patients at
high risk of systemic infections. e.g patients who are anticipated to have profound or prolonged neutropenia such as during bone marrow
transplantation, the recommended dose is 400 mg daily. Start dosage several days before anticipated onset of neutropenia and continue for seven days
after the neutrophil count rises above 100 cells per mm.
SIDE-EFFECTS:
Fluconazole is generally well tolerated. The commonest side-eects associated Fluconazole are symptoms associated with the gastrointestinal tract; these
include nausea, abdominal discomfort, diarrhoea and atulence. Other adverse events such as rash are rarely encountered (Incidence less than 1%). In rare
cases, as with other azoles, anaphylaxis has been reported.
See “warnings” for information on hepatic necrosis and cutaneous reaction in AIDS patients
Reviews
There are no reviews yet.